Targets › GRPR
8 programs from 5 companies in 13 trials: 11 Phase 1, 2 Phase 2; Oncology; next expected readout Dec 2026.
Receptor for gastrin-releasing peptide (GRP). Signals via association with G proteins that activate a phosphatidylinositol-calcium second messenger system, resulting in Akt phosphorylation. (UniProt, P30550)
Open in Phaseline: the race on GRPR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | [177Lu]Lu-PSMA-617 PSMA-targeted radioligand therapy with lutetium-177 | FOLH1, GRPR | Phase 2 | Metastatic Castration-Resistant Prostate Cancer (mCRPC); Metastatic Neuroendocrine Prostate Cancer; Metastatic Castration-resistant Prostate Cancer | Jan 2027 |
| Novartis | [177Lu]Lu-NeoB GRPR-targeted radioligand therapy | GRPR | Phase 1 | Breast Cancer; Newly Diagnosed and Recurrent Glioblastoma | Dec 2026 |
| First Affiliated Hospital of Fujian Medical University | 68Ga-G21 GRPR-targeted PET imaging agent | GRPR | Phase 1 | Prostate Cancer (Adenocarcinoma) | Dec 2026 |
| First Affiliated Hospital of Fujian Medical University | 68Ga-G23 GRPR-targeted PET imaging agent | GRPR | Phase 1 | Prostate Cancer (Adenocarcinoma) | Dec 2026 |
| Orano Med Theranostics, SAS | ²¹²Pb-DOTAM-GRPR1 GRPR-targeted antagonist radioimmunoconjugate with lead-212 | GRPR | Phase 1 | Cervical Cancer | Jan 2027 |
| Alpha-9 Oncology USA | [177Lu]Lu-A9-0631 Lutetium-177 labeled GRPR-targeting peptide | GRPR | Phase 1 | Breast Cancer | Dec 2028 |
| Alpha-9 Oncology USA | [225Ac]Ac-A9-0642 Actinium-225 labeled GRPR-targeting peptide | GRPR | Phase 1 | Breast Cancer | Dec 2028 |
| Eli Lilly | LY4257496 GRPR-targeting therapeutic (mechanism to be determined in Phase 1) | GRPR | Phase 1 | Breast Neoplasms | Apr 2030 |
Breast Cancer (4) Metastatic Neuroendocrine Prostate Cancer (2) Prostate Cancer (Adenocarcinoma) (2) Metastatic Castration-Resistant Prostate Cancer (mCRPC) (1) Metastatic Castration-resistant Prostate Cancer (1) Newly Diagnosed and Recurrent Glioblastoma (1) Cervical Cancer (1) Breast Neoplasms (1)
small molecule (7), mixed (1)
Novartis (2) First Affiliated Hospital of Fujian Medical University (2) Alpha-9 Oncology USA (2) Orano Med Theranostics, SAS (1) Eli Lilly (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.